‘We designed Spectra to boost both dentistry and the patient knowledge, and these glowing product reviews are telling clinicians that our design is right on the tag.’ Using fluorescence technology, Spectra emits safe high-energy LED light onto the tooth surface area. The dentist or hygienist views the tooth on a display screen then, which clearly shows both a color and numerical reading to precisely indicate the living and extent of any decay, calculus or plaque. Spectra is the only handheld caries detection device one in the marketplace with these capabilities. By enabling hygienists and dentists to find caries in early stages, Spectra technology might help prevent unnecessary excavation and allow dental procedures to noninvasively restore even more teeth to health.We are gratified and encouraged by this strong display of support from a superb band of leading life sciences investors, said Tom van Haarlem, MD, CEO and President of Aerie. Glaucoma is certainly still the second leading cause of visible disability and blindness nowadays. We are excited about the potential for Aerie’s compounds to offer multiple, differentiated and improved treatment options for millions of patients experiencing this widespread, degenerative disease. With the funding, Dennis Henner, PhD, Handling Director at Clarus Ventures, joined Aerie’s Board of Directors. Related StoriesAllergan completes acquisition of AqueSysEnvisia's ENV515 meets principal efficacy endpoint in phase 2a glaucoma trialAllergan enters into agreement to acquire Aquesys and its XEN45 plan The more we find out about the unique, clinical benefits of AR-12286, the more enthusiastic we are about its prospects as an important and differentiated glaucoma treatment, both as monotherapy and in combination with existing glaucoma drugs, said Dr.